Cline Scientific provides updates on StemCART project

As previously communicated, Cline Scientific AB is planning to undertake an ex-vivo proof-of-concept pilot study using human cartilage later in 2021. In order to get to this goal, Cline, together with clinicians and other advisors, are designing the experiments and preparing the application for ethical approval from the Swedish Ethical Review Authority. This application will outline Cline’s research plan, timeline and tissue sourcing. Once approved the permit will allow Cline to use human cartilage tissue in testing.

These tests will represent another step forward for bringing StemCART into in-human clinical trials. If successful, manufacturing process development and the necessary preclinical safety studies will begin in 2022. The expected year of commencement of first-in-human clinical trial is 2023.

StemCART aims to be a game-changer in the global osteoarthritis market by regenerating damaged cartilage through allogeneic iPSC-derived chondrocytes, obtained through Cline’s unique nanotechnology.

“The results and development of StemCART over the last year have been very encouraging, and we are excited to be planning the first testing of StemCART on human cartilage, alongside our collaborating clinicians. The potential benefit for osteoarthritis patients is significant and we look forward to providing investors with more developments and updates.” Says Patrik Sundh CEO.

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase